Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Louis Jacques On Coverage, Evidence And IDEs

This article was originally published in The Pink Sheet Daily

Executive Summary

Former CMS coverage director Louis Jacques talks about the strong future ahead he envisions for the Medicare coverage-with-evidence-development program and new coverage policies that will be implemented for investigational device exemption trials.

You may also be interested in...



Cohesive Coverage-With-Evidence Authority Needed For Medicare, Lawmakers Told

Former CMS coverage chief Louis Jacques told House lawmakers that the agency’s authority to implement coverage-with-evidence-development policies are fragmented, hindering application of the program.

CMS Coverage Group Changes Management, But Not Priorities

Director of CMS’ Coverage and Analysis Group Louis Jacques will leave the agency in March; his replacement, Deputy Tamara Syrek Jensen, will continue to make Coverage with Evidence Development a top priority.

CDRH Preps New Program To Streamline Approval-To-Reimbursement Path

The device center is in the very early stages of launching the “CDRH Reimbursement Program,” planning to go beyond its current parallel-review collaboration with CMS to work with device firms, CMS and private payers to streamline the pathway from market approval to reimbursement.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS076967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel